Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $575 | Backorder | |
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | MBC-11 trisodium has potential to treat tumor-induced bone disease (TIBD).It is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. |
In vitro | MBC-11 decreases KAS-6/1 cell growth from approximately 56% at 10-8 M to 6% at 10-5 M[1].MBC-11 shows similar activity profiles and significantly inhibits growth of all three cell lines between 10-8 and 10-4 M. |
In vivo | These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for tumor-induced bone disease (TIBD)[1].MBC-11 (0.04 μg/day, s.c.) has a lower incidence of bone metastases of 40% compared to those treated with PBS (90%) or 0.04 μg/day zoledronate (100%).?MBC-11 also significantly decreases bone tumor burden compared to PBS- or zoledronate-treated mice[1].?Weight gained in mice treated with up to 500 μg/day of MBC-11 is similar to the PBS treated group[1]. |
Molecular Weight | 577.16 |
Formula | C11H17N3Na3O14P3 |
Cas No. | 387877-45-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | H2O: 125 mg/mL (216.58 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.